Molecular Subtype
Anaplastic Large Cell Lymphoma, ALK-Positive
CI-CAN-00001801Explore in graph →
Hematologic6 active trials
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00001801Explore in graph →
Clinical trials
20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03505554 | A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma(CRU3) | completed | Phase 2 | 9 | University of Milano BicoccaOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | completed | Phase 2 | 77 | BeiGeneINDUSTRY | 5 | Oct 26, 2024 | clinicaltrials |
| NCT01979536 | Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2024 | clinicaltrials |
| NCT02561273 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 54 | University of NebraskaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03603847 | Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma | completed | — | 41 | The Lymphoma Academic Research OrganisationOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02419287 | Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas | completed | Phase 2 | 12 | University of Milano BicoccaOTHER | 1 | Mar 6, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jun 10, 2026source: clinicaltrials